Horizon Therapeutics PLC reports results for the quarter ended in March - Earnings Summary

Horizon Therapeutics

03/05/2023 13:54

* Horizon Therapeutics PLC  HZNP.OQ  reported quarterly
adjusted
earnings of 83 cents​​ per share for the quarter ended in March.
The mean expectation of eight analysts for the quarter was
for earnings of $1.12 per share.
    * Revenue fell 6% to $832.06 million from a year ago;
analysts
expected $902.28 million. 
    * Horizon Therapeutics PLC's reported EPS for the quarter
was 23
cents​.
    * The mean earnings estimate of analysts had risen by
about 2.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Horizon Therapeutics PLC shares had risen by 2.4% this
quarter and lost 1.8% so far this year.
    * The company reported quarterly net income of $54.68
million.
    * Wall Street's median 12-month price target for Horizon
Therapeutics PLC is $116.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 7
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
3 at 12:54 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      1.12           0.83           Missed
 Dec. 31 2022      1.09           1.21           Beat
 Sep. 30 2022      1.01           1.25           Beat
 Jun. 30 2022      1.34           1.07           Missed